$VOR

Stifel reiterated a Buy rating and $40 price target for Vor Biopharma (VOR) after its earnings update, citing Phase 3 trial enrollment completion. The stock trades at $19.68, with a Strong Buy consensus and targets ranging from $27 to $50. Stifel expects top-line data in 2027 and sees potential in telitacicept for treating autoimmune diseases. The stock has surged 42% in six months and 50% year-to-date, but is above fair value according to InvestingPro.

Vor Biopharma reported a net loss of $86.7M in 3Q 2026, narrower than the $812.7M loss a year earlier, with no revenue in either period. The company completed enrollment in the UPSTREAM MG trial and plans to start Phase 3 trials for ocular myasthenia gravis and Sjogren's disease in 2027. R&D spending increased for telitacicept programs while declining for legacy programs.

Vor Bio (VOR) reported final results from a Phase 3 trial of telitacicept in adults with IgA nephropathy. The trial met its primary endpoint, showing a significant improvement in kidney function compared to placebo. Telitacicept reduced the risk of kidney function decline and proteinuria. Adverse events were more frequent with telitacicept but serious events were less common. Vor Bio holds exclusive rights outside China.

Vor Bio (VOR) granted stock options for 59,250 shares and RSUs for 12,550 shares to new hires. Options have a $18.06 exercise price, vesting over four years. RSUs also vest over four years. Grants comply with Nasdaq Rule 5635(c)(4).

Vor Bio completed enrollment in its Phase 3 UPSTREAM MG trial for telitacicept, a treatment for generalized myasthenia gravis, with results expected in early 2027. The company plans to start a Phase 3 trial for ocular myasthenia gravis in the same timeframe, expanding its telitacicept franchise. The trials follow positive results from RemeGen's Phase 3 trial in China.

Biotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.

Vor Bio (Nasdaq: VOR) appointed David Zaccardelli, Pharm.D., to its Board of Directors. The company said he has led biopharma companies through late-stage development and commercialization, including Verona Pharma until its Oct 2025 acquisition by Merck for $10B. Vor also noted Andrew Levin stepped down as an advisor.

Vor Biopharma Inc. (VOR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001817229 false 0001817229 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 06,

Vor Bio (Nasdaq: VOR) said its Compensation Committee granted inducement awards on July 1, 2026 to seven newly hired employees under Nasdaq Rule 5635(c)(4). Awards include stock options for 71,200 shares (10-year term, $18.39 exercise price) and RSUs for 15,150 shares. Options and RSUs vest over four years subject to continued employment.

Vor Biopharma Inc. (VOR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 vor-ex10_1.htm EX-10.1 EX-10.1 321452236 v8 Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan Adopted by the Board of Directors: April 16, 2026 Approved by the Stockholders: June 11, 2026 321452236 v8 Table of Contents Page 1. General. 1 2. Shares Subje